Partnership for Safe Medicines Releases Action Plan to Protect Patients from Unapproved Knockoff GLP-1s
Plan serves as policy roadmap to strengthen America’s gold standard patient safety system
The Partnership for Safe Medicines today published a report outlining solutions to protect patients from the risks of a growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety Systemserves as a detailed plan for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.
Today, emboldened by a lack of regulatory enforcement, telehealth companies and compounding entities are producing and marketing large volumes of unapproved compounded medications. These deceptively advertised compounded drugs carry significant risks for patients because they exist outside of the FDA’s rigorous review and approval system and they raise concerns about transparency and informed decision-making. PSM’s new report is a call to action for stricter enforcement of compounding violations, foreign imports and deceptive marketing and the development and implementation of new laws and policies that will help keep patients safe.
